Table 2. Health care effects and costs after diagnosis of hepatocellular carcinoma by treatment strategies, 2007–2010.
| Treatment strategies | Effects (mean, 95% CI) | Costs* (mean, 95% CI) | |
|---|---|---|---|
| PYLL | QALYL | ||
| No Treatment or BSC (n = 960) | 11.5710 (11.2764–11.8655) | 10.6226 (10.3531–10.8921) | $36,415 ($33,782-$39,048) |
| TACE alone or TACE + Sorafenib (n = 53) | 10.7860 (9.5982–11.9739) | 10.0879 (9.0078–11.1680) | $45,638 ($39,180-$52,096) |
| Non-sorafenib chemotherapy alone (n = 66) | 12.4255 (11.3347–13.5163) | 11.5722 (10.5770–12.5675) | $51,657 ($38,913-$64,402) |
| Sorafenib alone (n = 93) | 10.4988 (9.6655–11.3320) | 9.7664 (9.0062–10.5266) | $53,198 ($44,941-$61,456) |
*All costs reflect 2013 US$ per person.
BSC, best supportive care; TACE, transarterial chemoembolization; CI, confidence intervals; PYLL, potential years of life lost (a measure of premature mortality); QALYL, quality-adjusted life years lost.